- Low-intensity extracorporeal shock wave therapy (LiESWT) for erectile dysfunction (ED) is well-tolerated with short-term benefits.
Why this matters
- LiESWT is widely used to treat ED, even though the FDA has not approved it for this purpose.
- Researchers analyzed 7 randomized controlled trials assessing LiESWT as a treatment for ED (N=607; mean age, 57-65 years).
- Funding: Medispec Ltd.
- 6 of 7 trials provided data on International Index of Erectile Function-Erectile Function (IIEF-EF) scores at 1 month follow-up; mean difference between treatment and sham was a statistically significant increase in IIEF-EF of 4.23 (95% CI, 0.94-7.53; P=.012).
- 5 of 7 trials provided data on patients with a baseline erectile hardness score (EHS) ≤2 who improved to EHS ≥3 at 1-month follow-up; pooled relative risk of EHS improvement for treatment vs sham was 6.63 (95% CI, 1.59-27.71; P=.0095).
- 5 trials reported no adverse events or side effects; 2 reported some patients in both treatment and sham groups experienced local irritation after treatment.
- Long-term results were not available; most trial endpoints were assessed at 1 month after treatment.
- No trials included intention-to-treat analyses.